CD40
CD40 sits on the cells that teach T cells what to attack. Agonist antibodies press it to turn cold tumours hot; the strongest signals so far are in pancreatic cancer with chemotherapy.
Overview
CD40 (chromosome 20q13.12) is the receptor for CD40 ligand (TNFSF5/CD40LG) and transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells; it is expressed in B cells and in primary carcinomas (UniProt P25942). On activation, CD40 licenses dendritic cells to promote antitumour T-cell activation and re-educates macrophages to destroy tumour stroma; numerous agonist antibodies have been tolerable, with mild to moderate transient cytokine release, antitumour activity in melanoma, and major regressions in pancreatic cancer and mesothelioma with chemotherapy (Vonderheide 2020, Annu Rev Med). In the corpus, selicrelumab's intratumoural study ended with the end of drug development (NCT03892525) and mitazalimab is entering a phase 2/3 study with chemotherapy (NCT07437287).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CD40 sits on the cells that teach T cells what to attack. Agonist antibodies press it to turn cold tumours hot; the strongest signals so far are in pancreatic cancer with chemotherapy.
- 1 · What it is
CD40 sits on the cells that teach T cells what to attack. Agonist antibodies press it to turn cold tumours hot; the strongest signals so far are in pancreatic cancer with chemotherapy.
- 2 · What goes wrong in cancer
A TNF-receptor-superfamily member on antigen-presenting cells; the target of the CD40 agonist technology.
- 3 · How drugs use it
No product in this corpus aims at CD40 yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
External identifiers
Sources: HGNC HGNC:11919 (approved symbol, name, aliases and cross-references); UniProt P25942 (protein name, function and tissue specificity)
Biology
A TNF-receptor-superfamily member on antigen-presenting cells; the target of the CD40 agonist technology.
- B cells and primary carcinomas (UniProt P25942)
- Dendritic cells and macrophages, per Vonderheide 2020
- Pancreatic cancer trials of CD40 agonists
Notes
top- Prevalence not recorded: HGNC and UniProt carry no positivity rates.
Latest papers
topQuery for this target: (TITLE:"CD40" OR ABSTRACT:"CD40" OR TITLE:"TNFRSF5" OR ABSTRACT:"TNFRSF5" OR TITLE:"CD40 molecule" OR ABSTRACT:"CD40 molecule" OR TITLE:"Bp50" OR ABSTRACT:"Bp50" OR TITLE:"p50" OR ABSTRACT:"p50") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD40, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetHHLA2 (B7-H7)
Shares CD28, The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetSiglec-10
Shares Macrophage, The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD86 (B7-2)
Shares CD28, The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD24
Shares Macrophage, The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetInterleukin-10 (IL10)
Shares Macrophage, The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD39 (ENTPD1)
Shares The cancer-immunity cycle, Checkpoint (two meanings), Pancreatic ductal adenocarcinoma and the tag checkpoint-map.
- TargetAdenosine A2A receptor (ADORA2A)
Shares The cancer-immunity cycle, Checkpoint (two meanings), Pancreatic ductal adenocarcinoma and the tag checkpoint-map.
- TargetTDO2
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.